AstraZeneca Plc - Product Pipeline Review - 2016

  • ID: 3691131
  • Company Profile
  • 369 pages
  • Global Markets Direct
  • Astrazeneca PLC
1 of 4
AstraZeneca Plc - Product Pipeline Review - 2016

Summary

‘AstraZeneca Plc - Product Pipeline Review - 2016’, provides an overview of the AstraZeneca Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AstraZeneca Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of AstraZeneca Plc
- The report provides overview of AstraZeneca Plc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses AstraZeneca Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features AstraZeneca Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate AstraZeneca Plc’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for AstraZeneca Plc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding AstraZeneca Plc’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

AstraZeneca Plc Snapshot

AstraZeneca Plc Overview

Key Information

Key Facts

AstraZeneca Plc - Research and Development Overview

Key Therapeutic Areas

AstraZeneca Plc - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

AstraZeneca Plc - Pipeline Products Glance

AstraZeneca Plc - Late Stage Pipeline Products

AstraZeneca Plc - Clinical Stage Pipeline Products

AstraZeneca Plc - Early Stage Pipeline Products

AstraZeneca Plc - Drug Profiles

(avibactam + ceftazidime)

(dapagliflozin propanediol + saxagliptin)

(formoterol fumarate + glycopyrrolate)

(metformin hydrochloride + saxagliptin)

brodalumab

cangrelor tetrasodium

cediranib maleate

ceftaroline fosamil

dapagliflozin propanediol

osimertinib mesylate

propofol

ticagrelor

(aclidinium bromide + formoterol fumarate)

(budesonide + formoterol fumarate + glycopyrrolate)

(dapagliflozin propanediol + metformin hydrochloride + saxagliptin)

fulvestrant

gefitinib

glycopyrrolate

olaparib

omega-3-carboxylic acids

PT-009

quetiapine fumarate ER

roxadustat

selumetinib sulfate

AZD-3293

AZD-4547

(avibactam sodium + ceftaroline fosamil)

abediterol napadisylate

AZD-1775

AZD-1981

AZD-2014

AZD-3241

AZD-3759

AZD-4017

AZD-5363

AZD-7594

AZD-7624

AZD-9150

interferon beta-1a

lesogaberan

PT-008

RDEA-3170

sapitinib

saracatinib difumarate

savolitinib

Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease

AZD-5069

AZD-5312

(allopurinol + lesinurad)

(avibactam sodium + aztreonam lysine)

(insulin human + pramlintide acetate)

ARC-165395XX

AZD-0156

AZD-0424

AZD-3965

AZD-4076

AZD-5634

AZD-5718

AZD-6738

AZD-7451

AZD-7986

AZD-8108

AZD-8186

AZD-8835

AZD-8871

AZD-8999

AZD-9496

AZD-9567

dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide

LAS-40468

MEDI-7352

AC-163794

ADP-31417

ADP-71296

AZ-12260493

AZ-12441970

AZ-12861903

AZ-13483342

AZ-20

AZ-4217

AZ-4425

AZ-64

AZ-709

AZ-876

AZD-0449

AZD-2098

AZD-2858

AZD-3463

AZD-3857

AZD-4831

AZD-9708

CWGNC-41

Drug 1 for Cancer

Drug 2 for Cancer

Drug 3 for Cancer

Drug 4 for Cancer

Drug 5 for Cancer

Drug 6 for Cancer

HTL-1071

KU-59403

LAS-191351

LAS-194871

LCB-010200

MMV-253

Monoclonal Antibody Conjugates for Oncology

NBTI-5463

NKTR-119

OX-CLI

PL-8905

Small Molecule for Malaria

Small Molecule for Oncology

Small Molecule to Antagonize Histamine 3 Receptor for Cognition

Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology

Small Molecule to Block Kv1.5 for Atrial Fibrillation

Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia

Small Molecule to Inhibit PI3K Beta for Bleeding and Clotting Disorders

Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia

Small Molecules 1 for Malaria

Small Molecules for Dyslipidemia and Hypertriglyceridemia

Small Molecules to Antagonize GPR103 for Obesity

Small Molecules to Antagonize M3 Receptors for Respiratory Disorders

Small Molecules to Antagonize P2X3 for Chronic Pain

Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis

Small Molecules to Inhibit DNA GyrB for Tuberculosis

Small Molecules to Inhibit DprE1 for Tuberculosis

Synthetic Peptide for Neuropathic Pain

VU-0467154

AZ-0108

AZ-12201182

AZ-27

AZ-465

AZ-6142

AZ-82

AZD-3147

Drugs for Cardiovascular Diseases

HD-001

Small Molecule 1 for Malaria

Small Molecule to Inhibit 11beta-HSD-1 for Type 2 Diabetes

Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis

Small Molecules for Diabetic Nephropathy

Small Molecules for Tuberculosis

Small Molecules to Inhibit Acetohydroxyacid Synthase for Mycobacterium Infections

Small Molecules to Inhibit ATP Synthesis for Tuberculosis

Small Molecules to Inhibit Carboxypeptidase U for Thrombosis

Small Molecules to Inhibit DNA Gyrase B for Tuberculosis

Small Molecules to Inhibit DXP-Reductoisomerase for Malaria

Small Molecules to Inhibit MALT-1 for Oncology and Autoimmune Disorders

Small Molecules to Inhibit p38alpha MAP Kinase for Inflammatory Diseases

Small Molecules to Inhibit PLA2 for Undisclosed Indication

AstraZeneca Plc - Pipeline Analysis

AstraZeneca Plc - Pipeline Products by Target

AstraZeneca Plc - Pipeline Products by Route of Administration

AstraZeneca Plc - Pipeline Products by Molecule Type

AstraZeneca Plc - Pipeline Products by Mechanism of Action

AstraZeneca Plc - Recent Pipeline Updates

AstraZeneca Plc - Dormant Projects

AstraZeneca Plc - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

AstraZeneca Plc - Company Statement

AstraZeneca Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

AstraZeneca Plc - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

AstraZeneca Plc, Key Information

AstraZeneca Plc, Key Facts

AstraZeneca Plc - Pipeline by Indication, 2016

AstraZeneca Plc - Pipeline by Stage of Development, 2016

AstraZeneca Plc - Monotherapy Products in Pipeline, 2016

AstraZeneca Plc - Combination Treatment Modalities in Pipeline, 2016

AstraZeneca Plc - Partnered Products in Pipeline, 2016

AstraZeneca Plc - Partnered Products/ Combination Treatment Modalities, 2016

AstraZeneca Plc - Out-Licensed Products in Pipeline, 2016

AstraZeneca Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016

AstraZeneca Plc - Pre-Registration, 2016

AstraZeneca Plc - Filing rejected/Withdrawn, 2016

AstraZeneca Plc - Phase III, 2016

AstraZeneca Plc - Phase II, 2016

AstraZeneca Plc - Phase I, 2016

AstraZeneca Plc - Preclinical, 2016

AstraZeneca Plc - Discovery, 2016

AstraZeneca Plc - Pipeline by Target, 2016

AstraZeneca Plc - Pipeline by Route of Administration, 2016

AstraZeneca Plc - Pipeline by Molecule Type, 2016

AstraZeneca Plc - Pipeline Products by Mechanism of Action, 2016

AstraZeneca Plc - Recent Pipeline Updates, 2016

AstraZeneca Plc - Dormant Developmental Projects,2016

AstraZeneca Plc - Discontinued Pipeline Products, 2016

AstraZeneca Plc, Subsidiaries

AstraZeneca Plc, Key Manufacturing Facilities

List of Figures

AstraZeneca Plc - Pipeline by Top 10 Indication, 2016

AstraZeneca Plc - Pipeline by Stage of Development, 2016

AstraZeneca Plc - Monotherapy Products in Pipeline, 2016

AstraZeneca Plc - Combination Treatment Modalities in Pipeline, 2016

AstraZeneca Plc - Partnered Products in Pipeline, 2016

AstraZeneca Plc - Out-Licensed Products in Pipeline, 2016

AstraZeneca Plc - Pipeline by Top 10 Target, 2016

AstraZeneca Plc - Pipeline by Route of Administration, 2016

AstraZeneca Plc - Pipeline by Molecule Type, 2016

AstraZeneca Plc - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll